

Phase Ib/II of ARRY-614 plus either nivolumab or nivolumab+ipilimumab in advanced solid tumors

Status: OPEN TO ACCRUAL

Eligibility Criteria

Age:

Healthy Volunteers:

Conditions & Interventions

Interventions:

drug: Nivolumab, drug: Ipilimumab, drug: Arry-614, Modality: Immunotherapy

Conditions:

Melanoma, skin, Other Urinary, Urinary Bladder, Thyroid, Stomach, Soft Tissue, Small Intestine, Rectum, Prostate, Pancreas, Ovary, Other Respiratory and Intrathoracic Organs, Other Male Genital, Other Female Genital, Other Endocrine System, Other Digestive Organ, Lung, Liver, Lip, Oral Cavity and Pharynx, Larynx, Kidney, Eye and Orbit, Ill-Defined Sites, Esophagus, Corpus Uteri, Colon, Cervix, Breast, Brain and Nervous System, Bones and Joints

More Information

Contact(s): Osipova, Ekaterina - osipovak@vcu.edu

Principal Investigator: Poklepovic, Andrew, S

Phase: I/II

IRB

Number: HM20021810

System ID: NCT04074967

Thank you for choosing StudyFinder. Please visit <http://studyfinder.cctr.vcu.edu> to find a Study which is right for you and contact ctrrecruit@vcu.edu if you have questions or need assistance.